We recently demonstrated that pevonedistat, by blocking conjugation of the ubiquitin-like protein NEDD8 to its targets [11,12,13], is particularly effective in preclinical models of poorly differentiated, clinically aggressive CRC [14]. The gene discussed is NEDD8; the disease is colorectal carcinoma.